Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Allison Kalpakci, Mehmet Sofuoglu, Ismene Petrakis & Robert A. Rosenheck. (2018) Gender differences among Veterans with alcohol use disorder nationally in the Veterans Health Administration. Journal of Addictive Diseases 37:3-4, pages 185-194.
Read now
Read now
Articles from other publishers (25)
Margaret Paschen‐Wolff, Shelly F. Greenfield, R. Kathryn McHugh, Kathleen Burlew, Martina Pavlicova, Tse‐Hwei Choo, Celestina Barbosa‐Leiker, Lesia M. Ruglass, Sarah Mennenga, John Rotrosen, Edward V. Nunes & Aimee N. C. Campbell. (2023) Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine‐naloxone (BUP‐NX) or extended‐release naltrexone (XR‐NTX) for opioid use disorder. The American Journal on Addictions 32:6, pages 584-592.
Crossref
Crossref
Bryan Cruz, Valentina Vozella, Benjamin A. Carper, Joy C. Xu, Dean Kirson, Shawn Hirsch, Tracy Nolen, Lauren Bradley, Katie Fain, Meg Crawford, Thomas R. Kosten, Eric P. Zorrilla & Marisa Roberto. (2022) FKBP5 inhibitors modulate alcohol drinking and trauma-related behaviors in a model of comorbid post-traumatic stress and alcohol use disorder. Neuropsychopharmacology 48:8, pages 1144-1154.
Crossref
Crossref
Keisha Smith, Cheryl M. Lacadie, Verica Milivojevic, Nia Fogelman & Rajita Sinha. (2023) Sex differences in neural responses to stress and drug cues predicts future drug use in individuals with substance use disorder. Drug and Alcohol Dependence 244, pages 109794.
Crossref
Crossref
Eleanor Blair Towers, Ben Setaro & Wendy J. Lynch. (2023) Estradiol Enhances the Development of Addiction-Like Features in a Female Rat Model of Opioid Use Disorder. Neuroendocrinology 113:11, pages 1099-1111.
Crossref
Crossref
Margaret M. Paschen-Wolff, Jeremy D. Kidd & Emily Allen Paine. (2023) The State of the Research on Opioid Outcomes Among Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexuality- and Gender-Diverse Populations: A Scoping Review. LGBT Health 10:1, pages 1-17.
Crossref
Crossref
Kyle R. Samson, Wei Xu, Sandhya Kortagere & Rodrigo A. España. (2022) Intermittent access to oxycodone decreases dopamine uptake in the nucleus accumbens core during abstinence. Addiction Biology 27:6.
Crossref
Crossref
Mariangela Antonelli, Luisa Sestito, Claudia Tarli & Giovanni Addolorato. (2022) Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. European Journal of Internal Medicine 103, pages 13-22.
Crossref
Crossref
Lauren A. Walter, Savannah Bunnell, Kathryn Wiesendanger & Alyson J. McGregor. (2022) Sex, gender, and the opioid epidemic: Crucial implications for acute care. AEM Education and Training 6:S1.
Crossref
Crossref
Christopher J. Hammond, Grace Park, Annabel Kady, Krutika Rathod, Naisa Rahman, Carol Vidal, Kevin Wenzel & Marc Fishman. (2022) Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders. Journal of Substance Abuse Treatment 133, pages 108495.
Crossref
Crossref
Céline Nicolas, Natalie E. Zlebnik, Mehdi Farokhnia, Lorenzo Leggio, Satoshi Ikemoto & Yavin Shaham. (2022) Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. Pharmacological Reviews 74:1, pages 119-140.
Crossref
Crossref
Marco Venniro, Ingrid Reverte, Leslie A. Ramsey, Kimberly M. Papastrat, Ginevra D’Ottavio, Michele Stanislaw Milella, Xuan Li, Jeffrey W. Grimm & Daniele Caprioli. (2021) Factors modulating the incubation of drug and non-drug craving and their clinical implications. Neuroscience & Biobehavioral Reviews 131, pages 847-864.
Crossref
Crossref
Susanne Rösner & Michael Soyka. (2021) Anti-Craving-Substanzen bei Alkoholabhängigkeit. Nervenheilkunde 40:08, pages 623-627.
Crossref
Crossref
Teddy G. Goetz, Jill B. Becker & Carolyn M. Mazure. (2021) Women, opioid use and addiction. The FASEB Journal 35:2.
Crossref
Crossref
Alisa B. Busch, Shelly F. Greenfield, Sharon Reif, Sharon-Lise T. Normand & Haiden A. Huskamp. (2020) Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment. Journal of Substance Abuse Treatment 115, pages 108040.
Crossref
Crossref
Sandra D. Comer, Paolo Mannelli, Danesh Alam, Antoine Douaihy, Narinder Nangia, Sarah C. Akerman, Abigail Zavod, Bernard L. Silverman & Maria A. Sullivan. (2020) Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. The American Journal on Addictions 29:4, pages 313-322.
Crossref
Crossref
Richard J. Bodnar. (2020) Endogenous opiates and behavior: 2017. Peptides 124, pages 170223.
Crossref
Crossref
Andreea C. Brabete, Lorraine Greaves, Natalie Hemsing & Julie Stinson. (2020) Sex- and Gender-Based Analysis in Cannabis Treatment Outcomes: A Systematic Review. International Journal of Environmental Research and Public Health 17:3, pages 872.
Crossref
Crossref
Andrew S. Huhn, Meredith S. Berry & Kelly E. Dunn. (2019) Review: Sex‐Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder. The American Journal on Addictions 28:4, pages 246-261.
Crossref
Crossref
Yasmin Schmid, Alexander Navarini, Zita-Rose Manjaly Thomas, Bettina Pfleiderer, Stephan Krähenbühl & Simon M Mueller. (2019) Sex differences in the pharmacology of itch therapies—a narrative review. Current Opinion in Pharmacology 46, pages 122-142.
Crossref
Crossref
Kristin Klemmetsby Solli, Zill-e-Huma Latif, Arild Opheim, Peter Krajci, Kamni Sharma-Haase, Jūratė Šaltytė Benth, Lars Tanum & Nikolaj Kunoe. (2018) Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. Addiction 113:10, pages 1840-1849.
Crossref
Crossref
Brantley P. Jarvis, August F. Holtyn, Shrinidhi Subramaniam, D. Andrew Tompkins, Emmanuel A. Oga, George E. Bigelow & Kenneth Silverman. (2018) Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 113:7, pages 1188-1209.
Crossref
Crossref
Adam Bisaga, Paolo Mannelli, Miao Yu, Narinder Nangia, Christine E. Graham, D. Andrew Tompkins, Thomas R. Kosten, Sarah C. Akerman, Bernard L. Silverman & Maria A. Sullivan. (2018) Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug and Alcohol Dependence 187, pages 171-178.
Crossref
Crossref
Steven J. Nieto, Cana B. Quave & Therese A. Kosten. (2018) Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats. Pharmacology Biochemistry and Behavior 167, pages 50-59.
Crossref
Crossref
Shannon Smith-Bernardin, Chris Rowe, Emily Behar, Michelle Geier, Stuart Washington, Glenn-Milo Santos, Jason Euren, Judith Martin, Alice Gleghorn & Phillip O. Coffin. (2018) Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study. Journal of Substance Abuse Treatment 85, pages 109-115.
Crossref
Crossref
Andrew L. Koons, Marna Rayl Greenberg, Robert D. Cannon & Gillian A. Beauchamp. (2018) Women and the Experience of Pain and Opioid Use Disorder: A Literature-based Commentary. Clinical Therapeutics 40:2, pages 190-196.
Crossref
Crossref